Internal Deadline (Application): Junior Investigator Global ATTR Cardiac Amyloidosis Research
This competitive grant program seeks to support research proposals from Junior Investigators that advance our understanding of the early diagnosis and treatment of ATTR Cardiac amyloidosis.
Pfizer is interested in supporting research proposals that are focused in the following areas:
- Approaches for the early identification and follow up of ATTR Cardiac Amyloidosis patients.
- RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR Cardiac Amyloidosis.
- Evaluation of patients with ATTR Cardiac Amyloidosis presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy).
Individual projects requesting up to $100k will be considered. Pfizer anticipates funding up to 4 projects.
Full details about this call are available.
Internal deadline: April 22, 2024. Contact email is ird@dal.ca
Funder deadline: May 6, 2024
Time